The estimated Net Worth of Mark J Enyedy is at least $24.1 Миллион dollars as of 2 February 2024. Mr. Enyedy owns over 51,234 units of Immunogen stock worth over $18,884,705 and over the last 10 years he sold IMGN stock worth over $1,297,634. In addition, he makes $3,917,560 as President, Chief Executive Officer и Director at Immunogen.
Sign up
Mr. Enyedy IMGN stock SEC Form 4 insiders trading
Mark has made over 8 trades of the Immunogen stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 51,234 units of IMGN stock worth $1,600,550 on 2 February 2024.
The largest trade he's ever made was exercising 3,119,375 units of Immunogen stock on 2 August 2023 worth over $15,066,581. On average, Mark trades about 82,867 units every 64 days since 2014. As of 2 February 2024 he still owns at least 604,504 units of Immunogen stock.
You can see the complete history of Mr. Enyedy stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mark Enyedy biography
Mark J. Enyedy J.D. serves as President, Chief Executive Officer, Director of the Company. Prior to joining ImmunoGen, he served in various executive capacities at Shire PLC, a pharmaceutical company, from 2013 to 2016, including as Executive Vice President and Head of Corporate Development from 2014 to 2016, where he led Shire’s strategy, M&A and corporate planning functions and provided commercial oversight of Shire’s pre-Phase 3 portfolio. Prior to joining Shire, he served as Chief Executive Officer and a director of Proteostasis Therapeutics, Inc., a biopharmaceutical company, from 2011 to 2013. Prior to joining Proteostasis, he served for 15 years at Genzyme Corporation, a biopharmaceutical company, most recently as President of the Transplant, Oncology, and Multiple Sclerosis divisions. Mr. Enyedy holds a JD from Harvard Law School and practiced law prior to joining Genzyme. Mr. Enyedy is also a director of Akebia Therapeutics, LogicBio Therapeutics, Inc., and The American Cancer Society of Eastern New England. Within the past five years, he also served as a director of Fate Therapeutics, Inc. and Keryx Biopharmaceuticals, Inc.
What is the salary of Mark Enyedy?
As the President, Chief Executive Officer и Director of Immunogen, the total compensation of Mark Enyedy at Immunogen is $3,917,560. There are no executives at Immunogen getting paid more.
How old is Mark Enyedy?
Mark Enyedy is 56, he's been the President, Chief Executive Officer и Director of Immunogen since 2016. There are 10 older and 6 younger executives at Immunogen. The oldest executive at Immunogen, Inc. is Richard Wallace, 68, who is the Independent Director.
What's Mark Enyedy's mailing address?
Mark's mailing address filed with the SEC is C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO STREET, SAN RAFAEL, CA, 94901.
Insiders trading at Immunogen
Over the last 21 years, insiders at Immunogen have traded over $72,947,831 worth of Immunogen stock and bought 303,125 units worth $974,603 . The most active insiders traders include Biochem Incshire Pharmaceut..., Capital, L.P.Morton Holding... и Mark J Enyedy. On average, Immunogen executives and independent directors trade stock every 34 days with the average trade being worth of $2,554,057. The most recent stock trade was executed by Stacy Ann Coen on 2 February 2024, trading 14,350 units of IMGN stock currently worth $448,294.
What does Immunogen do?
immunogen is a clinical-stage biotechnology company that develops targeted anticancer therapeutics with its proprietary antibody-drug conjugate (adc) technology. the company's lead product candidate, mirvetuximab soravtansine, is a potential treatment for folate receptor α-positive ovarian cancers and other solid tumors. leading healthcare companies have licensed rights to use immunogen's technology to develop novel anticancer therapies, and roche's marketed product, kadcyla, utilizes immunogen's adc technology. more information about the company can be found at www.immunogen.com.
What does Immunogen's logo look like?
Complete history of Mr. Enyedy stock trades at Akebia Therapeutics, Biomarin Pharmaceutical, Fate Therapeutics Inc, Immunogen и ContextLogic Inc
Immunogen executives and stock owners
Immunogen executives and other stock owners filed with the SEC include:
-
Mark Enyedy,
President, Chief Executive Officer, Director -
Anna Berkenblit,
Senior Vice President and Chief Medical Officer -
Thomas Ryll,
Vice President, Technical Operations -
Mark Joseph Enyedy,
Pres, CEO & Director -
Dr. Anna Berkenblit,
Sr. VP & Chief Medical Officer -
Dr. Theresa G. Wingrove,
Sr. VP of Regulatory Affairs & Quality -
Stacy A. Coen,
Sr. VP & Chief Bus. Officer -
Stephen McCluski,
Independent Chairman of the Board -
Kristine Peterson,
Independent Director -
Richard Wallace,
Independent Director -
Dean Mitchell,
Independent Director -
Mark Goldberg,
Independent Director -
Stuart Arbuckle,
Independent Director -
Theresa Wingrove,
Senior Vice President - Regulatory Affairs and Quality -
Stacy Coen,
Senior Vice President and Chief Business Officer -
Susan Altschuller,
Chief Financial Officer, Senior Vice President -
Kristen Harrington-Smith,
Sr. VP & Chief Commercial Officer -
Audrey Bergan,
VP & Chief HR Officer -
Courtney O'Konek,
Sr. Director of Corp. Communications & Investor Relations -
Dr. Thomas Ryll,
Sr. VP of Technical Operations -
Renee Lentini,
VP of Fin., Principal Accounting Officer & Corp. Controller -
Peter J. Williams,
VP, Business Development -
John Lambert,
Senior Vice President -
Joseph J Villafranca,
Director -
Richard J. Gregory,
Executive VP & CSO -
Charles Q Morris,
Executive VP & CDO -
Daniel M Junius,
Chief Financial Officer -
David Brannon Johnston,
Chief Financial Officer -
Ellie Harrison,
VP & Chief HR Officer -
Howard H Pien,
Director -
Lauren White,
SVP, CFO AND PFO -
David G Foster,
V.P.-Fin., Prin. Acctg. Off. -
Blaine H. Mc Kee,
EVP & Chief Business Officer -
Nicole Onetto,
Director -
Craig Barrows,
Executive VP, General Counsel -
Sandra Poole,
Senior VP, Tech Operations -
Mark B Skaletsky,
Director -
Gregory D Perry,
Chief Financial Officer -
James J O'leary,
Vice President -
Biochem Incshire Pharmaceut...,
-
Karleen Marie Oberton,
Senior Corporate Controller -
Virginia Lavery,
VP and Senior Controller -
Gregg Beloff,
Vice President and CFO -
Christopher U Missling,
Chief Financial Officer -
Capital, L.P.Morton Holding...,
-
David Warren Carter,
Director -
Mitchel Sayare,
Chief Executive Officer -
John Tagliamonte,
VP, Business Development -
Stuart Feiner,
Director -
Pauline Jen Ryan,
VP Business Development -
Walter Blattler,
Executive Vice President -
Isabel Kalofonos,
SVP & CHIEF COMMERCIAL OFFICER -
Tracey L Mc Cain,
Director -
Michael Vasconcelles,
EVP R&D & MEDICAL AFFAIRS -
Daniel Char,
SVP & CHIEF LEGAL OFFICER -
Helen M. Thackray,
Director -
Kristen Harrington Smith,
SVP & CHIEF COMMERCIAL OFFICER -
Renee Lentini,
VP & PRIN ACCTG OFFICER